admin | November 23, 2023
Topline Results from a 12-Week Phase 2a Trial (DUET) Evaluating TERN-501, a Highly Selective Thyroid Hormone Receptor (THR) β Agonist, Either as Monotherapy or in Combination with TERN-101, a Nonsteroidal Farnesoid X Receptor (FXR) Agonist, Demonstrated Significant Reductions in MR-Based Liver Fat Content and Fibroinflammation in Patients with Presumed MASH
![Topline Results from a 12-Week Phase 2a Trial (DUET) Evaluating TERN-501, a Highly Selective Thyroid Hormone Receptor (THR) β Agonist, Either as Monotherapy or in Combination with TERN-101, a Nonsteroidal Farnesoid X Receptor (FXR) Agonist, Demonstrated Significant Reductions in MR-Based Liver Fat Content and Fibroinflammation in Patients with Presumed MASH]()
